Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington’s Disease Mice
Tóm tắt
Disturbance of rapid eye movement (REM) sleep appears early in both patients with Huntington’s disease (HD) and mouse models of HD. Selective serotonin reuptake inhibitors are widely prescribed for patients with HD, and are also known to suppress REM sleep in healthy subjects. To test whether selective serotonin reuptake inhibitors can correct abnormal REM sleep and sleep-dependent brain oscillations in HD mice, we treated wild-type and symptomatic R6/2 mice acutely with vehicle and paroxetine (5, 10, and 20 mg/kg). In addition, we treated a group of R6/2 mice chronically with vehicle or paroxetine (20 mg/kg/day) for 8 weeks, with treatment starting before the onset of overt motor symptoms. During and after treatment, we recorded electroencephalogram/electromyogram from the mice. We found that both acute and chronic paroxetine treatment normalized REM sleep in R6/2 mice. However, only chronic paroxetine treatment prevented the emergence of abnormal low-gamma (25–45 Hz) electroencephalogram oscillations in R6/2 mice, an effect that persisted for at least 2 weeks after treatment stopped. Chronic paroxetine treatment also normalized REM sleep theta rhythm in R6/2 mice, but, interestingly, this effect was restricted to the treatment period. By contrast, acute paroxetine treatment slowed REM sleep theta rhythm in WT mice but had no effect on abnormal theta or low-gamma oscillations in R6/2 mice. Our data show that paroxetine treatment, when initiated before the onset of symptoms, corrects both REM sleep disturbances and abnormal brain oscillations, suggesting a possible mechanistic link between early disruption of REM sleep and the subsequent abnormal brain activity in HD mice.
Tài liệu tham khảo
Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci 2005;17:496-502.
Lazar AS, Panin F, Goodman AO, et al. Sleep deficits but no metabolic deficits in premanifest Huntington's disease. Ann Neurol 2015;78:630-648.
Aziz NA, Anguelova GV, Marinus J, Lammers GJ, Roos RA. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat Disord 2010;16:345-350.
Goodman AO, Rogers L, Pilsworth S, et al. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr Neurol Neurosci Rep 2011;11:211-217.
Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008;65:482-488.
Piano C, Losurdo A, Della Marca G, et al. Polysomnographic findings and clinical correlates in Huntington disease: a cross-sectional cohort study. Sleep 2015;38:1489-1495.
Piano C, Mazzucchi E, Bentivoglio AR, et al. Wake and sleep EEG in patients with Huntington Disease: an eLORETA study and review of the literature. Clin EEG Neurosci 2017;48:60-71.
Silvestri R, Raffaele M, De Domenico P, et al. Sleep features in Tourette's syndrome, neuroacanthocytosis and Huntington's chorea. Neurophysiol Clin 1995;25:66-77.
Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ. Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation. Brain 2013;136:2147-2158.
Kantor S, Varga J, Morton AJ. A single dose of hypnotic corrects sleep and EEG abnormalities in symptomatic Huntington's disease mice. Neuropharmacology 2016;105:298-307.
Fisher SP, Black SW, Schwartz MD, et al. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease. Brain 2013;136:2159-2172.
Lebreton F, Cayzac S, Pietropaolo S, Jeantet Y, Cho YH. Sleep physiology alterations precede plethoric phenotypic changes in R6/1 Huntington's disease mice. PLOS ONE 2015;10:e0126972.
Fisher SP, Schwartz MD, Wurts-Black S, et al. Quantitative electroencephalographic analysis provides an early-stage indicator of disease onset and progression in the zQ175 knock-in mouse model of Huntington's disease. Sleep 2016;39:379-391.
Pignatelli M, Lebreton F, Cho YH, Leinekugel X. "Ectopic" theta oscillations and interictal activity during slow-wave state in the R6/1 mouse model of Huntington's disease. Neurobiol Dis 2012;48:409-417.
Jeantet Y, Cayzac S, Cho YH. Beta oscillation during slow wave sleep and rapid eye movement sleep in the electroencephalogram of a transgenic mouse model of Huntington's disease. PLOS ONE 2013;8:e79509.
Hong SL, Cossyleon D, Hussain WA, Walker LJ, Barton SJ, Rebec GV. Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington's disease. PLOS ONE 2012;7:e47026.
Callahan JW, Abercrombie ED. Relationship between subthalamic nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse model of Huntington's disease. J Physiol 2015;593:3727-3738.
Loh DH, Kudo T, Truong D, Wu Y, Colwell CS. The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep. PLOS ONE 2013;8:e69993.
Nagy D, Tingley FD, 3rd, Stoiljkovic M, Hajos M. Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor. Exp Neurol 2015;263:122-131.
Lopez J, Roffwarg HP, Dreher A, Bissette G, Karolewicz B, Shaffery JP. Rapid eye movement sleep deprivation decreases long-term potentiation stability and affects some glutamatergic signaling proteins during hippocampal development. Neuroscience 2008;153:44-53.
Shaffery JP, Lopez J, Roffwarg HP. Brain-derived neurotrophic factor (BDNF) reverses the effects of rapid eye movement sleep deprivation (REMSD) on developmentally regulated, long-term potentiation (LTP) in visual cortex slices. Neurosci Lett 2012;513:84-88.
Shaffery JP, Sinton CM, Bissette G, Roffwarg HP, Marks GA. Rapid eye movement sleep deprivation modifies expression of long-term potentiation in visual cortex of immature rats. Neuroscience 2002;110:431-443.
Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83-98.
Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5:181-197.
Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65:927-947.
Smith MI, Piper DC, Duxon MS, Upton N. Effect of SB-243213, a selective 5-HT(2C) receptor antagonist, on the rat sleep profile: a comparison to paroxetine. Pharmacol Biochem Behav 2002;71:599-605.
Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 2004;55:590-594.
Sillaber I, Panhuysen M, Henniger MS, et al. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 2008;200:557-572.
Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev 2012;92:1087-1187.
Weber F, Chung S, Beier KT, Xu M, Luo L, Dan Y. Control of REM sleep by ventral medulla GABAergic neurons. Nature 2015;526:435-438.
Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev 2011;15:269-281.
David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 2003;140:1128-1136.
Bylsma FW, Peyser CE, Folstein SE, Folstein MF, Ross C, Brandt J. EEG power spectra in Huntington's disease: clinical and neuropsychological correlates. Neuropsychologia 1994;32:137-150.
Gerbrandt LK, Lawrence JC, Eckardt MJ, Lloyd RL. Origin of the neocortically monitored theta rhythm in the curarized rat. Electroencephalogr Clin Neurophysiol 1978;45:454-467.
Kantor S, Jakus R, Molnar E, et al. Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra. J Pharmacol Exp Ther 2005;315:921-930.
Jackson J, Dickson CT, Bland BH. Median raphe stimulation disrupts hippocampal theta via rapid inhibition and state-dependent phase reset of theta-related neural circuitry. J Neurophysiol 2008;99:3009-3026.
Munn RG, McNaughton N. Effects of fluoxetine on hippocampal rhythmic slow activity and behavioural inhibition. Behav Pharmacol 2008;19:257-264.
Ly S, Pishdari B, Lok LL, Hajos M, Kocsis B. Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci 2013;4:191-199.
Ciamei A, Detloff PJ, Morton AJ. Progression of behavioural despair in R6/2 and Hdh knock-in mouse models recapitulates depression in Huntington's disease. Behav Brain Res 2015;291:140-146.
Farzan F, Barr MS, Levinson AJ, et al. Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia. Brain 2010;133:1505-1514.
Tekell JL, Hoffmann R, Hendrickse W, Greene RW, Rush AJ, Armitage R. High frequency EEG activity during sleep: characteristics in schizophrenia and depression. Clin EEG Neurosci 2005;36:25-35.
van Deursen JA, Vuurman EF, Verhey FR, van Kranen-Mastenbroek VH, Riedel WJ. Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment. J Neural Transm (Vienna) 2008;115:1301-1311.
Engel AK, Fries P, Singer W. Dynamic predictions: oscillations and synchrony in top-down processing. Nat Rev Neurosci 2001;2:704-716.
Gruber T, Muller MM, Keil A. Modulation of induced gamma band responses in a perceptual learning task in the human EEG. J Cogn Neurosci 2002;14:732-744.
Fell J, Fernandez G, Klaver P, Elger CE, Fries P. Is synchronized neuronal gamma activity relevant for selective attention? Brain Res Brain Res Rev 2003;42:265-272.
Dine J, Genewsky A, Hladky F, et al. Local optogenetic induction of fast (20-40 Hz) pyramidal-interneuron network oscillations in the in vitro and in vivo CA1 hippocampus: modulation by CRF and enforcement of perirhinal theta activity. Front Cell Neurosci 2016;10:108.
Middleton SJ, Racca C, Cunningham MO, et al. High-frequency network oscillations in cerebellar cortex. Neuron 2008;58:763-774.
Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 1997;17:2295-2313.
Huang Y, Morozov A. Hippocampal deletion of BDNF gene attenuates gamma oscillations in area CA1 by up-regulating 5-HT3 receptor. PLOS ONE 2011;6:e16480.
Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007;81:294-330.
Martinez-Turrillas R, Del Rio J, Frechilla D. Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 2005;49:1178-1188.
Grote HE, Bull ND, Howard ML, et al. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 2005;22:2081-2088.
Jang SW, Liu X, Chan CB, et al. Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 2009;16:644-656.
Datta S, Knapp CM, Koul-Tiwari R, Barnes A. The homeostatic regulation of REM sleep: a role for localized expression of brain-derived neurotrophic factor in the brainstem. Behav Brain Res 2015;292:381-392.
Ravassard P, Hamieh AM, Malleret G, Salin PA. Paradoxical sleep: a vigilance state to gate long-term brain plasticity? Neurobiol Learn Mem 2015;122:4-10.